O-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a crucial biomarker in glioblastoma (GBM) that influences response to temozolomide. Traditional detection methods, such as gene sequencing, are time-consuming and limited to postope...
PURPOSE: Machine Learning (ML) has become an essential tool for analyzing biomedical data, facilitating the prediction of treatment outcomes and patient survival. However, the effectiveness of ML models heavily relies on both the choice of algorithms...
We aimed to build a robust classifier for the MGMT methylation status of glioblastoma in multiparametric MRI. We focused on multi-habitat deep image descriptors as our basic focus. A subset of the BRATS 2021 MGMT methylation dataset containing both M...
Cancer imaging : the official publication of the International Cancer Imaging Society
Dec 23, 2024
OBJECTIVE: This study aims to evaluate the effectiveness of deep learning features derived from multi-sequence magnetic resonance imaging (MRI) in determining the O-methylguanine-DNA methyltransferase (MGMT) promoter methylation status among glioblas...
Glioblastoma is an aggressive brain cancer with a poor prognosis. The O6-methylguanine-DNA methyltransferase (MGMT) gene methylation status is crucial for treatment stratification, yet economic constraints often limit access. This study aims to devel...
The number of studies on deep learning for medical diagnosis is expanding, and these systems are often claimed to outperform clinicians. However, only a few systems have shown medical efficacy. From this perspective, we examine a wide range of deep l...
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. The standard treatment for GBM consists of surgical resection followed by concurrent chemoradiotherapy and adjuvant temozolomide. O-6-methylguanine-DNA methyltransferase (...
OBJECTIVE: The aim of this study was to build a convolutional neural network (CNN)-based prediction model of glioblastoma (GBM) molecular subtype diagnosis and prognosis with multimodal features.
This retrospective study has been conducted to validate the performance of deep learning-based survival models in glioblastoma (GBM) patients alongside the Cox proportional hazards model (CoxPH) and the random survival forest (RSF). Furthermore, the ...
AJNR. American journal of neuroradiology
Mar 4, 2021
BACKGROUND AND PURPOSE: () promoter methylation confers an improved prognosis and treatment response in gliomas. We developed a deep learning network for determining promoter methylation status using T2 weighted Images (T2WI) only.
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.